Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Dyslipidemias HELP
Based on 26,090 articles published since 2010
|||| 11 

These are the 26090 published articles about Dyslipidemias that originated from Worldwide during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. 2019

Précoma, Dalton Bertolim / Oliveira, Gláucia Maria Moraes de / Simão, Antonio Felipe / Dutra, Oscar Pereira / Coelho, Otávio Rizzi / Izar, Maria Cristina de Oliveira / Póvoa, Rui Manuel Dos Santos / Giuliano, Isabela de Carlos Back / Alencar Filho, Aristóteles Comte de / Machado, Carlos Alberto / Scherr, Carlos / Fonseca, Francisco Antonio Helfenstein / Santos Filho, Raul Dias Dos / Carvalho, Tales de / Avezum, Álvaro / Esporcatte, Roberto / Nascimento, Bruno Ramos / Brasil, David de Pádua / Soares, Gabriel Porto / Villela, Paolo Blanco / Ferreira, Roberto Muniz / Martins, Wolney de Andrade / Sposito, Andrei C / Halpern, Bruno / Saraiva, José Francisco Kerr / Carvalho, Luiz Sergio Fernandes / Tambascia, Marcos Antônio / Coelho-Filho, Otávio Rizzi / Bertolami, Adriana / Correa Filho, Harry / Xavier, Hermes Toros / Faria-Neto, José Rocha / Bertolami, Marcelo Chiara / Giraldez, Viviane Zorzanelli Rocha / Brandão, Andrea Araújo / Feitosa, Audes Diógenes de Magalhães / Amodeo, Celso / Souza, Dilma do Socorro Moraes de / Barbosa, Eduardo Costa Duarte / Malachias, Marcus Vinícius Bolívar / Souza, Weimar Kunz Sebba Barroso de / Costa, Fernando Augusto Alves da / Rivera, Ivan Romero / Pellanda, Lucia Campos / Silva, Maria Alayde Mendonça da / Achutti, Aloyzio Cechella / Langowiski, André Ribeiro / Lantieri, Carla Janice Baister / Scholz, Jaqueline Ribeiro / Ismael, Silvia Maria Cury / Ayoub, José Carlos Aidar / Scala, Luiz César Nazário / Neves, Mario Fritsch / Jardim, Paulo Cesar Brandão Veiga / Fuchs, Sandra Cristina Pereira Costa / Jardim, Thiago de Souza Veiga / Moriguchi, Emilio Hideyuki / Schneider, Jamil Cherem / Assad, Marcelo Heitor Vieira / Kaiser, Sergio Emanuel / Lottenberg, Ana Maria / Magnoni, Carlos Daniel / Miname, Marcio Hiroshi / Lara, Roberta Soares / Herdy, Artur Haddad / Araújo, Cláudio Gil Soares de / Milani, Mauricio / Silva, Miguel Morita Fernandes da / Stein, Ricardo / Lucchese, Fernando Antonio / Nobre, Fernando / Griz, Hermilo Borba / Magalhães, Lucélia Batista Neves Cunha / Borba, Mario Henrique Elesbão de / Pontes, Mauro Ricardo Nunes / Mourilhe-Rocha, Ricardo. ·Pontifícia Universidade Católica do Paraná (PUC-PR), Curitiba, PR - Brazil. · Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, PR - Brazil. · Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ - Brazil. · Instituto de Cardiologia de Santa Catarina, São José, SC - Brazil. · Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS - Brazil. · Universidade Estadual de Campinas (UNICAMP), Campina, SP - Brazil. · Universidade Federal de São Paulo (UNIFESP), São Paulo, SP - Brazil. · Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC - Brazil. · Universidade Federal do Amazonas (UFAM), Manaus, AM - Brazil. · Ministério da Saúde, Brasília, DF - Brazil. · Instituto do Coração (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), São Paulo, SP - Brazil. · Hospital Israelita Albert Einstein, São Paulo, SP - Brazil. · Clínica Cardiosport de Prevenção e Reabilitação, Florianópolis, SC - Brazil. · Departamento de Ergometria e Reabilitação Cardiovascular da Sociedade Brazileira de Cardiologia (DERC/SBC), Rio de Janeiro, RJ - Brazil. · Universidade do Estado de Santa Catarina (UDESC), Florianópolis, SC - Brazil. · Hospital Alemão Oswaldo Cruz, São Paulo, SP - Brazil. · Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ - Brazil. · Hospital Pró-Cardíaco, Rio de Janeiro, RJ - Brazil. · Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG - Brazil. · Faculdade de Ciências Médicas de Minas Gerias (CMMG) da Fundação Educacional Lucas Machado (FELUMA), Belo Horizonte, MG - Brazil. · Hospital Universitário Ciências Médicas (HUCM), Belo Horizonte, MG - Brazil. · Universidade Federal de Lavas (UFLA), Lavras, MG - Brazil. · Universidade de Vassouras, Vassouras, RJ - Brazil. · Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ - Brazil. · Hospital Samaritano, Rio de Janeiro, RJ - Brazil. · Universidade Federal Fluminense (UFF), Niterói, RJ - Brazil. · Complexo Hospitalar de Niterói, Niterói, RJ - Brazil. · Universidade de São Paulo (USP), São Paulo, SP - Brazil. · Saraiva & Berlinger LTDA, São Paulo, SP - Brazil. · Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil. · Pronto Cardio, Santos, SP - Brazil. · Real Hospital Português de Beneficência, Recife, PE - Brazil. · Universidade Federal do Pará (UFPA), Belém, PA - Brazil. · Liga Hipertensão de Porto Alegre, Porto Alegre, RS - Brazil. · Liga de Hipertensão Arterial da Faculdade de Medicina da Universidade Federal de Goiás (UFG), Goiânia, GO - Brazil. · FGM Clínica Paulista de Doenças Cardiovasculares, São Paulo, SP - Brazil. · Universidade Federal de Alagoas (UFAL), Maceió, AL - Brazil. · Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS - Brazil. · Fundação Universitária de cardiologia do RS (ICFUC), Porto Alegre, RS - Brazil. · Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS - Brazil. · Secretaria de Estado da Saúde do Paraná, Curitiba, PR - Brazil. · Instituto de Cardiologia Preventiva de São Caetano do Sul, São Caetano do Sul, SP - Brazil. · Hospital do Coração (HCor), São Paulo, SP - Brazil. · Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP - Brazil. · Instituto de Moléstias Cardiovasculares, São José do Rio Preto, SP - Brazil. · Universidade Federal de Mato Grosso (UFMT), Cuiabá, MT - Brazil. · Universidade Federal de Goiás (UFG), Goiânia, GO - Brazil. · SOS Cardio, Florianópolis, SC - Brazil. · Universidade do Sul de SC (Unisul), Florianópolis, SC - Brazil. · Instituto Nacional de Cardiologia do Rio de Janeiro, Rio de Janeiro, RJ - Brazil. · Laboratório de Lípides (LIM10), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, São Paulo, SP - Brazil. · Instituto de Nutrição Roberta Lara, Itu, SP - Brazil. · Diadia Nutrição e Gastronomia, Itu, SP - Brazil. · CLINIMEX, Rio de Janeiro, RJ - Brazil. · Fitcordis Medicina do Exercício, Brasília, DF - Brazil. · Universidade Federal do Paraná (UFPR), Curitiba, PR - Brazil. · Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS - Brazil. · Hospital Santa Joana Recife, Recife, PE - Brazil. · Hospital Agamenon Magalhães, Recife, PE - Brazil. · Universidade Federal da Bahia (UFBA), Salvador, BA - Brazil. · Hospital São Francisco, Porto Alegre, RS - Brazil. ·Arq Bras Cardiol · Pubmed #31691761.

ABSTRACT: -- No abstract --

2 Guideline [European dyslipidemia guidelines 2019 : What is new?] 2019

Katzmann, J L / Tünnemann-Tarr, A / Laufs, U. ·Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland. julius.katzmann@medizin.uni-leipzig.de. · Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland. ·Herz · Pubmed #31650209.

ABSTRACT: In August 2019 the updated dyslipidemia guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) were published. Since the last version from 2016, important large randomized trials especially with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and new genetic analyses have become available that show additional reduction of atherosclerotic cardiovascular disease (ASCVD) risk on top of the previously recommended treatments. Based on these data the main concept of the recommendations is achieving an early and as large as possible absolute reduction of low-density lipoprotein cholesterol (LDL-C). As a result of this knowledge and the extended pharmaceutical treatment options the LDL‑C goals are amended to lower values. Patients at very high cardiovascular risk are recommended to achieve LDL‑C <1.4 mmol/l (55 mg/dl). For patients with high, moderate, and low cardiovascular risks, LDL‑C goals are set at <1.8 mmol/l (70 mg/dl), <2.6 mmol/l (100 mg/dl) and <3.0 mmol/l (116 mg/dl), respectively. A new classification of patients with recurrent cardiovascular events despite maximum tolerated statin-based therapy is introduced. For these patients the LDL‑C goal is <1.0 mmol/l (40 mg/dl). Novel recommendations comprise a more precise classification of patients at low or moderate risk based on cardiovascular imaging, recommendations for familial hypercholesterolemia, screening for increased lipoprotein(a) and determination of apolipoprotein B as diagnostic and therapeutic goal.

3 Guideline 2018 Guidelines for the management of dyslipidemia. 2019

Rhee, Eun-Jung / Kim, Hyeon Chang / Kim, Jae Hyeon / Lee, Eun Young / Kim, Byung Jin / Kim, Eun Mi / Song, YoonJu / Lim, Jeong Hyun / Kim, Hae Jin / Choi, Seonghoon / Moon, Min Kyong / Na, Jin Oh / Park, Kwang-Yeol / Oh, Mi Sun / Han, Sang Youb / Noh, Junghyun / Yi, Kyung Hee / Lee, Sang-Hak / Hong, Soon-Cheol / Jeong, In-Kyung. ·Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. · Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Nutrition and Dietetics, Kangbuk Samsung Hospital, Seoul, Korea. · Department of Food Science and Nutrition, The Catholic University of Korea, Bucheon, Korea. · Department of Food Service and Nutrition Care, Seoul National University Hospital, Seoul, Korea. · Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. · Division of Cardiology, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea. · Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea. · Cardiovascular Center, Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. · Department of Neurology, Chung-Ang University College of Medicine, Seoul, Korea. · Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea. · Divisions of Nephrology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. · Divisions of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. · Department of Pediatrics, Wonkwang University Sanbon Medical Center, Gunpo, Korea. · Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. · Department of Obstetrics and Gynecology, Korea University Medical Center, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea. ·Korean J Intern Med · Pubmed #31272142.

ABSTRACT:

4 Guideline Translating AHA/ACC cholesterol guidelines into meaningful risk reduction. 2019

Wójcik, Cezary / Shapiro, Michael D. ·Department of Family Medicine, Oregon Health & Science University, Portland, USA. Email: cezarywojcik2000@gmail.com. · Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, USA. ·J Fam Pract · Pubmed #31226173.

ABSTRACT: The new recommendations detail refined, personalized lipid management and emphasize multiple levels of evidence. The result? Care is more complex but patients might benefit more.

5 Guideline 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. 2019

Grundy, Scott M / Stone, Neil J / Anonymous2231083. ·University of Texas Southwestern Medical Center, Dallas, Texas (S.M.G.). · Northwestern University Feinberg School of Medicine, Chicago, Illinois (N.J.S.). ·Ann Intern Med · Pubmed #31132793.

ABSTRACT: Description: In November 2018, the American Heart Association and American College of Cardiology (AHA/ACC) released a new clinical practice guideline on cholesterol management. It was accompanied by a risk assessment report on primary prevention of atherosclerotic cardiovascular disease (ASCVD). Methods: A panel of experts free of recent and relevant industry-related conflicts was chosen to carry out systematic reviews and meta-analyses of randomized controlled trials (RCTs) that examined cardiovascular outcomes. High-quality observational studies were used for estimation of ASCVD risk. An independent panel systematically reviewed RCT evidence about the benefits and risks of adding nonstatin medications to statin therapy compared with receiving statin therapy alone in persons who have or are at high risk for ASCVD. Recommendation: The guideline endorses a heart-healthy lifestyle beginning in childhood to reduce lifetime risk for ASCVD. It contains several new features compared with the 2013 guideline. For secondary prevention, patients at very high risk may be candidates for adding nonstatin medications (ezetimibe or proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors) to statin therapy. In primary prevention, a clinician-patient risk discussion is still strongly recommended before a decision is made about statin treatment. The AHA/ACC risk calculator first triages patients into 4 risk categories. Those at intermediate risk deserve a focused clinician-patient discussion before initiation of statin therapy. Among intermediate-risk patients, identification of risk-enhancing factors and coronary artery calcium testing can assist in the decision to use a statin. Compared with the 2013 guideline, the new guideline gives more attention to percentage reduction in low-density lipoprotein cholesterol as a treatment goal and to long-term monitoring of therapeutic efficacy. To simplify monitoring, nonfasting lipid measurements are allowed.

6 Guideline Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019. 2019

Ascaso, Juan Francisco / Civeira, Fernando / Guijarro, Carlos / López Miranda, José / Masana, Luis / Mostaza, José María / Pedro-Botet, Juan / Pintó, Xavier / Valdivielso, Pedro. ·Hospital Clínico, Universidad de Valencia, CIBERDEM, Valencia, España. · Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Universidad de Zaragoza, Zaragoza, España. · Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Alcorcón, Madrid, España. · Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBEROBN, Córdoba, España. · Hospital Universitario de Reus, Universidad Rovira y Virgili, IISPV, CIBERDEM, Reus, Tarragona, España. · Hospital Carlos III, Madrid, España. · Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España. · Hospital Universitario de Bellvitge-Idibell, Universidad de Barcelona, CIBEROBN, Hospitalet de Llobregat, Barcelona, España. Electronic address: xpinto@bellvitgehospital.cat. · Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España. ·Clin Investig Arterioscler · Pubmed #31130361.

ABSTRACT: A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use.

7 Guideline The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. 2019

Jia, Xiaoming / Al Rifai, Mahmoud / Birnbaum, Yochai / Smith, Sidney C / Virani, Salim S. ·Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. · Department of Medicine, University of Kansas School of Medicine, Wichita, KS, USA. · Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. · Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. · Division of Cardiology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. · Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. virani@bcm.edu. · Health Policy, Quality and Informatics Program, Health Services Research and Development Center for Innovations, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX, 77030, USA. virani@bcm.edu. · Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. virani@bcm.edu. ·Curr Atheroscler Rep · Pubmed #30941517.

ABSTRACT: PURPOSE OF REVIEW: The 2018 ACC/AHA Multisociety blood cholesterol guidelines provide updated recommendations based on contemporary evidence on the management of serum cholesterol for the prevention of atherosclerotic cardiovascular disease (ASCVD) events. This review discusses clinically important topics in the new guidelines related to secondary ASCVD prevention. RECENT FINDINGS: Since the 2013 ACC/AHA blood cholesterol guidelines, several large randomized control trials involving ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab) have been published. The trials provided evidence that these non-statin, LDL-cholesterol lowering agents are efficacious in reducing risk for ASCVD events in patients with clinical ASCVD. The 2018 guidelines incorporate these new findings into updated clinical recommendations on therapeutic strategies related to the use of ezetimibe and PCSK9 inhibitors. The guidelines also recommend risk stratification of secondary prevention patients to identify those at very high-risk of ASCVD events as these patients would derive the most absolute risk reduction from the addition of non-statin therapies. While high-intensity statins remain the first-line treatment to prevent recurrent ASCVD events in secondary prevention patients, ezetimibe and PCSK9 inhibitors are evidence-based non-statin agents that can be used when residual on top of maximally tolerated statin therapy in patients deemed to be at very-high risk of recurrent ASCVD events.

8 Guideline Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. 2019

LeRoith, Derek / Biessels, Geert Jan / Braithwaite, Susan S / Casanueva, Felipe F / Draznin, Boris / Halter, Jeffrey B / Hirsch, Irl B / McDonnell, Marie E / Molitch, Mark E / Murad, M Hassan / Sinclair, Alan J. ·Icahn School of Medicine at Mount Sinai, New York, New York. · University Medical Center Utrecht, Utrecht, Netherlands. · Presence Saint Francis Hospital, Evanston, Illinois. · Presence Saint Joseph Hospital, Chicago, Illinois. · Complejo Hospitalario Universitario de Santiago, CIBER de Fisiopatologia Obesidad y Nutricion, Instituto Salud Carlos III, Santiago de Compostela, Spain. · University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado. · University of Michigan, Ann Arbor, Michigan. · National University of Singapore, Singapore, Singapore. · University of Washington Medical Center-Roosevelt, Seattle, Washington. · Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. · Northwestern University Feinberg School of Medicine, Chicago, Illinois. · Division of Preventive Medicine, Mayo Clinic, Rochester, Minnesota. · King's College, London, United Kingdom. ·J Clin Endocrinol Metab · Pubmed #30903688.

ABSTRACT: OBJECTIVE: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. CONCLUSIONS: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

9 Guideline 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Arnett, Donna K / Blumenthal, Roger S / Albert, Michelle A / Buroker, Andrew B / Goldberger, Zachary D / Hahn, Ellen J / Himmelfarb, Cheryl Dennison / Khera, Amit / Lloyd-Jones, Donald / McEvoy, J William / Michos, Erin D / Miedema, Michael D / Muñoz, Daniel / Smith, Sidney C / Virani, Salim S / Williams, Kim A / Yeboah, Joseph / Ziaeian, Boback. · ·J Am Coll Cardiol · Pubmed #30894318.

ABSTRACT: -- No abstract --

10 Guideline Lipid-lowering drugs. 2019

Anonymous2860982. · ·Med Lett Drugs Ther · Pubmed #30845106.

ABSTRACT:

11 Guideline Document on a comprehensive approach to type 2 diabetes mellitus. 2019

Reyes-García, Rebeca / Moreno-Pérez, Óscar / Tejera-Pérez, Cristina / Fernández-García, Diego / Bellido-Castañeda, Virginia / de la Torre Casares, Martín López / Rozas-Moreno, Pedro / Fernández-García, José Carlos / Marco Martínez, Amparo / Escalada-San Martín, Javier / Gargallo-Fernández, Manuel / Botana-López, Manuel / López-Fernández, Judith / González-Clemente, José Miguel / Jódar-Gimeno, Esteban / Mezquita-Raya, Pedro / Anonymous651170. ·Unidad de Endocrinología y Nutrición, Hospital Universitario Torrecárdenas, Servicio de Endocrinología, Clínica San Pedro, Almería, España; Servicio de Endocrinología, Clínica San Pedro, Almería, España. Electronic address: rebeca.reyes.garcia@gmail.com. · Sección de Endocrinología y Nutrición, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-FISABIO), Alicante, España. · Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Ferrol, Ferrol, La Coruña, España. · Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Servicio Endocrinología y Nutrición, Hospital Vithas-Xanit, Benalmádena, Málaga, España. · Servicio de Endocrinología y Nutrición, Hospital Universitario Cruces, Baracaldo, Vizcaya, España. · Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen de las Nieves, Granada, España. · Servicio de Endocrinología y Nutrición. Hospital General Universitario de Ciudad Real, Ciudad Real, España. · Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, España; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), CB06/03, Instituto de Salud Carlos III, Madrid, España. · Endocrinología y Nutrición, Complejo Hospitalario de Toledo, Toledo, España; Hospital Quirón Salud Madrid, Madrid, España. · Departamento de Endocrinología y Nutrición, Clínica Universidad de Navarra; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, España; Grupo de Diabetes y Enfermedades Metabólicas, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España. · Sección de Endocrinología y Nutrición, Hospital Universitario Infanta Leonor, Madrid, España. · Sección de Endocrinología y Nutrición, Hospital Universitario Lucus Augusti, Lugo, España. · Servicio de Endocrinología y Nutrición, Hospital Universitario de Canarias, Departamento de Medicina, Universidad de La Laguna, Santa Cruz de Tenerife, España. · Servicio de Endocrinología y Nutrición, Hospital Parc Taulí, Instituto I3PT-UAB, DIAMET, CIBERDEM-ISCIII, Sabadell, Barcelona, España. · Hospitales Universitarios Quirón Salud, Ruber Juan Bravo y San José, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, España. · Unidad de Endocrinología y Nutrición, Hospital Universitario Torrecárdenas, Servicio de Endocrinología, Clínica San Pedro, Almería, España. ·Endocrinol Diabetes Nutr · Pubmed #30827909.

ABSTRACT: OBJECTIVE: Treatment of type 2 diabetes mellitus (T2DM) is complex and is intended to decrease morbidity and mortality. Management should therefore include adequate diabetes education, lifestyle changes, drug treatment to achieve early blood glucose control and reduction of cardiovascular (CV) risk factors, early detection and treatment of complications, and assessment of associated comorbidities. The objective was to prepare a document including all aspects required for a comprehensive approach to T2DM. PARTICIPANTS: Members of the Diabetes Mellitus Working Group of the Spanish Society of Endocrinology. METHODS: The available evidence regarding each aspect of diabetes management (blood glucose control goals, diet and exercise, drug treatment, risk factor management and control, detection of complications, and management of frail patients) was reviewed. Recommendations were formulated based on the grades of evidence stated in the 2018 Standards of Medical Care in Diabetes. Recommendations were discussed and agreed by the working group members. CONCLUSIONS: This document is intended to provide evidence-based practical recommendations for comprehensive management of T2DM by clinical endocrinologists.

12 Guideline Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. 2019

Elmets, Craig A / Leonardi, Craig L / Davis, Dawn M R / Gelfand, Joel M / Lichten, Jason / Mehta, Nehal N / Armstrong, April W / Connor, Cody / Cordoro, Kelly M / Elewski, Boni E / Gordon, Kenneth B / Gottlieb, Alice B / Kaplan, Daniel H / Kavanaugh, Arthur / Kivelevitch, Dario / Kiselica, Matthew / Korman, Neil J / Kroshinsky, Daniela / Lebwohl, Mark / Lim, Henry W / Paller, Amy S / Parra, Sylvia L / Pathy, Arun L / Prater, Elizabeth Farley / Rupani, Reena / Siegel, Michael / Stoff, Benjamin / Strober, Bruce E / Wong, Emily B / Wu, Jashin J / Hariharan, Vidhya / Menter, Alan. ·University of Alabama, Birmingham, Alabama. · Central Dermatology, St. Louis, Missouri. · Mayo Clinic, Rochester, Minnesota. · University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. · National Psoriasis Foundation, Portland, Oregon. · National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. · University of Southern California, Los Angeles, California. · Department of Dermatology, University of California San Francisco School of MedicineSan Francisco, California. · Medical College of Wisconsin, Milwaukee, Wisconsin. · Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York. · University of Pittsburgh, Pennsylvania. · University of California San Diego, San Diego, California. · Baylor Scott and White, Dallas, Texas. · University Hospitals Cleveland Medical Center, Cleveland, Ohio. · Massachusetts General Hospital, Boston, Massachusetts. · Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. · Northwestern University Feinberg School of Medicine, Chicago, Illinois. · Dermatology and Skin Surgery, Sumter, South Carolina. · Colorado Permanente Medical Group, Centennial, Colorado. · University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. · Icahn School of Medicine at Mount Sinai, New York, New York. · Emory University School of Medicine, Atlanta, Georgia. · University of Connecticut, Farmington, Connecticut; Probity Medical Research, Waterloo, Canada. · San Antonio Uniformed Services Health Education Consortium, Joint-Base San Antonio, Texas. · Dermatology Research and Education Foundation, Irvine, California. · American Academy of Dermatology, Rosemont, Illinois. Electronic address: vhariharan@aad.org. ·J Am Acad Dermatol · Pubmed #30772097.

ABSTRACT: Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence.

13 Guideline Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Wilson, Peter W F / Polonsky, Tamar S / Miedema, Michael D / Khera, Amit / Kosinski, Andrzej S / Kuvin, Jeffrey T. · ·Circulation · Pubmed #30586775.

ABSTRACT: BACKGROUND: The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol found little evidence to support the use of nonstatin lipid-modifying medications to reduce atherosclerotic cardiovascular disease (ASCVD) events. Since publication of these guidelines, multiple randomized controlled trials evaluating nonstatin lipid-modifying medications have been published. METHODS: We performed a systematic review to assess the magnitude of benefit and/or harm from additional lipid-modifying therapies compared with statins alone in individuals with known ASCVD or at high risk of ASCVD. We included data from randomized controlled trials with a sample size of >1 000 patients and designed for follow-up >1 year. We performed a comprehensive literature search and identified 10 randomized controlled trials for intensive review, including trials evaluating ezetimibe, niacin, cholesterol-ester transfer protein inhibitors, and PCSK9 inhibitors. The prespecified primary outcome for this review was a composite of fatal cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke. RESULTS: The cardiovascular benefit of nonstatin lipid-modifying therapies varied significantly according to the class of medication. There was evidence for reduced ASCVD morbidity with ezetimibe and 2 PSCK9 inhibitors. Reduced ASCVD mortality rate was reported for 1 PCSK9 inhibitor. The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) reduced the primary outcome by 1.8% over 7 years (hazard ratio: 0.90; 95% CI: 0.84-0.96], 7-year number needed to treat: 56). The PSCK9 inhibitor evolocumab in the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) decreased the primary outcome by 1.5% over 2.2 years (hazard ratio: 0.80; 95% CI: 0.73-0.88; 2.2=year number needed to treat: 67). In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab reduced the primary outcome by 1.6% over 2.8 years (hazard ratio: 0.86; 95% CI: 0.79-0.93; 2.8-year number needed to treat: 63). For ezetimibe and the PSCK9 inhibitors, rates of musculoskeletal, neurocognitive, gastrointestinal, or other adverse event risks did not differ between the treatment and control groups. For patients at high risk of ASCVD already on background statin therapy, there was minimal evidence for improved ASCVD risk or adverse events with cholesterol-ester transfer protein inhibitors. There was no evidence of benefit for the addition of niacin to statin therapy. Direct comparisons of the results of the 10 randomized controlled trials were limited by significant differences in sample size, duration of follow-up, and reported primary outcomes. CONCLUSIONS: In a systematic review of the evidence for adding nonstatin lipid-modifying therapies to statins to reduce ASCVD risk, we found evidence of benefit for ezetimibe and PCSK9 inhibitors but not for niacin or cholesterol-ester transfer protein inhibitors.

14 Guideline 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Grundy, Scott M / Stone, Neil J / Bailey, Alison L / Beam, Craig / Birtcher, Kim K / Blumenthal, Roger S / Braun, Lynne T / de Ferranti, Sarah / Faiella-Tommasino, Joseph / Forman, Daniel E / Goldberg, Ronald / Heidenreich, Paul A / Hlatky, Mark A / Jones, Daniel W / Lloyd-Jones, Donald / Lopez-Pajares, Nuria / Ndumele, Chiadi E / Orringer, Carl E / Peralta, Carmen A / Saseen, Joseph J / Smith, Sidney C / Sperling, Laurence / Virani, Salim S / Yeboah, Joseph. ·ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative. ·Circulation · Pubmed #30586774.

ABSTRACT: -- No abstract --

15 Guideline 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Grundy, Scott M / Stone, Neil J / Bailey, Alison L / Beam, Craig / Birtcher, Kim K / Blumenthal, Roger S / Braun, Lynne T / de Ferranti, Sarah / Faiella-Tommasino, Joseph / Forman, Daniel E / Goldberg, Ronald / Heidenreich, Paul A / Hlatky, Mark A / Jones, Daniel W / Lloyd-Jones, Donald / Lopez-Pajares, Nuria / Ndumele, Chiadi E / Orringer, Carl E / Peralta, Carmen A / Saseen, Joseph J / Smith, Sidney C / Sperling, Laurence / Virani, Salim S / Yeboah, Joseph. ·ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative. ·Circulation · Pubmed #30565953.

ABSTRACT: -- No abstract --

16 Guideline Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. 2019

Tuñón, José / Badimón, Lina / Bochaton-Piallat, Marie-Luce / Cariou, Bertrand / Daemen, Mat J / Egido, Jesus / Evans, Paul C / Hoefer, Imo E / Ketelhuth, Daniel F J / Lutgens, Esther / Matter, Christian M / Monaco, Claudia / Steffens, Sabine / Stroes, Erik / Vindis, Cécile / Weber, Christian / Bäck, Magnus. ·Department of Cardiology, Fundación Jiménez Díaz, Autónoma University and CiberCV, Avenida Reyes Católicos 2, Madrid, Spain. · Cardiovascular Sciences Institute (ICCC) and CiberCV, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. · University of Geneva, Geneva, Switzerland. · L'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. · Academic Medical Center, Amsterdam, The Netherlands. · Fundación Jiménez Díaz, Autónoma University and CIBERDEM, Madrid, Spain. · University of Sheffield, Sheffield, UK. · University Medical Centre Utrecht, Utrecht, Netherlands. · Karolinska Institutet, Stockholm, Sweden. · University of Amsterdam, Amsterdam, The Netherlands. · Ludwig-Maximilians-University, Munich, Germany. · German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. · University Heart Center, University Hospital Zurich, Zurich, Switzerland. · Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland. · Kennedy Institute, NDORMS, University of Oxford, Oxford, UK. · INSERM UMR-1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France. · Karolinska University Hospital, Stockholm, Sweden. ·Cardiovasc Res · Pubmed #30534957.

ABSTRACT: Dysregulated lipid metabolism induces an inflammatory and immune response leading to atherosclerosis. Conversely, inflammation may alter lipid metabolism. Recent treatment strategies in secondary prevention of atherosclerosis support beneficial effects of both anti-inflammatory and lipid-lowering therapies beyond current targets. There is a controversy about the possibility that anti-inflammatory effects of lipid-lowering therapy may be either independent or not of a decrease in low-density lipoprotein cholesterol. In this Position Paper, we critically interpret and integrate the results obtained in both experimental and clinical studies on anti-inflammatory actions of lipid-lowering therapy and the mechanisms involved. We highlight that: (i) besides decreasing cholesterol through different mechanisms, most lipid-lowering therapies share anti-inflammatory and immunomodulatory properties, and the anti-inflammatory response to lipid-lowering may be relevant to predict the effect of treatment, (ii) using surrogates for both lipid metabolism and inflammation as biomarkers or vascular inflammation imaging in future studies may contribute to a better understanding of the relative importance of different mechanisms of action, and (iii) comparative studies of further lipid lowering, anti-inflammation and a combination of both are crucial to identify effects that are specific or shared for each treatment strategy.

17 Guideline 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Grundy, Scott M / Stone, Neil J / Bailey, Alison L / Beam, Craig / Birtcher, Kim K / Blumenthal, Roger S / Braun, Lynne T / de Ferranti, Sarah / Faiella-Tommasino, Joseph / Forman, Daniel E / Goldberg, Ronald / Heidenreich, Paul A / Hlatky, Mark A / Jones, Daniel W / Lloyd-Jones, Donald / Lopez-Pajares, Nuria / Ndumele, Chiadi E / Orringer, Carl E / Peralta, Carmen A / Saseen, Joseph J / Smith, Sidney C / Sperling, Laurence / Virani, Salim S / Yeboah, Joseph. · ·J Am Coll Cardiol · Pubmed #30423393.

ABSTRACT: -- No abstract --

18 Guideline 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019

Grundy, Scott M / Stone, Neil J / Bailey, Alison L / Beam, Craig / Birtcher, Kim K / Blumenthal, Roger S / Braun, Lynne T / de Ferranti, Sarah / Faiella-Tommasino, Joseph / Forman, Daniel E / Goldberg, Ronald / Heidenreich, Paul A / Hlatky, Mark A / Jones, Daniel W / Lloyd-Jones, Donald / Lopez-Pajares, Nuria / Ndumele, Chiadi E / Orringer, Carl E / Peralta, Carmen A / Saseen, Joseph J / Smith, Sidney C / Sperling, Laurence / Virani, Salim S / Yeboah, Joseph. · ·J Am Coll Cardiol · Pubmed #30423391.

ABSTRACT: -- No abstract --

19 Guideline Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. 2018

Brunham, Liam R / Ruel, Isabelle / Aljenedil, Sumayah / Rivière, Jean-Baptiste / Baass, Alexis / Tu, Jack V / Mancini, G B John / Raggi, Paolo / Gupta, Milan / Couture, Patrick / Pearson, Glen J / Bergeron, Jean / Francis, Gordon A / McCrindle, Brian W / Morrison, Katherine / St-Pierre, Julie / Henderson, Mélanie / Hegele, Robert A / Genest, Jacques / Goguen, Jeannette / Gaudet, Daniel / Paré, Guillaume / Romney, Jacques / Ransom, Thomas / Bernard, Sophie / Katz, Pamela / Joy, Tisha R / Bewick, David / Brophy, James. ·Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: Liam.brunham@ubc.ca. · Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montréal, Quebec, Canada. · Department of Medicine, McGill University, Montréal, Quebec, Canada; Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada. · Faculty of Medicine, University of Toronto, Institute for Clinical Evaluative Sciences, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. · Department of Medicine, McMaster University, Hamilton, and Canadian Collaborative Research Network, Brampton, Ontario, Canada. · Departments of Medicine and Laboratory Medicine, CHU de Québec-Université Laval, Québec City, Quebec, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada. · Department of Pediatrics, The Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. · Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. · Department of Pediatrics, McGill University, Clinique 180, Montréal, Quebec, Canada. · Department of Pediatrics, Université de Montréal, CHU Sainte-Justine, Montréal, Quebec, Canada. · Departments of Medicine and Biochemistry, Schulich School of Medicine and Robarts Research Institute, Western University, London, Ontario, Canada. · Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montréal, Quebec, Canada; Department of Medicine, McGill University, Montréal, Quebec, Canada. · Department of Medicine, University of Toronto and Division of Endocrinology, St Michael's Hospital, Toronto Ontario, Canada. · Lipidology Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Saguenay, Quebec, Canada. · Department of Pathology and Molecular Medicine, Department of Clinical Epidemiology and Biostatistics, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada. · Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. · Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada; Department of Medicine, Division of Endocrinology, Université de Montreal, Montréal, Quebec, Canada. · Department of Medicine, Section of Endocrinology and Metabolism, University of Manitoba, St Boniface Hospital, Winnipeg, Manitoba, Canada. · Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. · Division of Cardiology, Department of Medicine, Dalhousie University, St John, New Brunswick, Canada. ·Can J Cardiol · Pubmed #30527143.

ABSTRACT: Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are undiagnosed. Herein, we provide an update of the 2014 Canadian Cardiovascular Society position statement on FH addressing the need for case identification, prompt recognition, and treatment with statins and ezetimibe, and cascade family screening. We provide a new Canadian definition for FH and tools for clinicians to make a diagnosis. The risk of atherosclerotic cardiovascular disease in patients with "definite" FH is 10- to 20-fold that of a normolipidemic individual and initiating treatment in youth or young adulthood can normalize life expectancy. Target levels for low-density lipoprotein cholesterol are proposed and are aligned with the Canadian Cardiovascular Society guidelines on dyslipidemia. Recommendation for the use of inhibitors of proprotein convertase kexin/subtilisin type 9 are made in patients who cannot achieve therapeutic low-density lipoprotein cholesterol targets on maximally tolerated statins and ezetimibe. The writing committee used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology in the preparation of the present document, which offers guidance for practical evaluation and management of patients with FH. This position statement also aims to raise awareness of FH nationally, and to mobilize patient support, promote knowledge translation, and availability of treatment and health care resources for this under-recognized, but important medical condition.

20 Guideline South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). 2018

Klug, E / Raal, F J / Marais, A D / Smuts, C M / Schamroth, C / Jankelow, D / Blom, D J / Webb, D A. ·Netcare Sunninghill and Sunward Park Hospitals, Division of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. drklug@tickerdoc.co.za. ·S Afr Med J · Pubmed #30421699.

ABSTRACT: South Africa (SA) is home to a heterogeneous population with a wide range of cardiovascular risk factors. Cholesterol reduction in combination with aggressive management of modifiable risk factors, including nutrition, physical activity, blood pressure and smoking, can help to reduce and prevent morbidity and mortality in individuals who are at increased risk of cardiovascular events. This updated consensus guide to management of dyslipidaemia in SA is based on the updated European Society of Cardiology and European Atherosclerosis Society dyslipidaemia guidelines published in 2016. For individuals who are not considered to be at high or very high cardiovascular risk, the decision whether to treat and which interventional strategy to use is based on a cardiovascular risk score calculated using total cholesterol, high-density lipoprotein cholesterol (HDL-C), gender, age and smoking status. The cardiovascular risk score refers to the 10-year risk of any cardiovascular event and includes 4 categories of risk (low, moderate, high and very high). People with established cardiovascular disease, diabetes mellitus, chronic kidney disease and genetic or severe dyslipidaemias are considered to already be at high or very high risk and do not require risk scoring. Therapeutic lifestyle change is the mainstay of management for all patients. The need for and intensity of drug therapy is determined according to baseline low-density lipoprotein (LDL-C) levels and the target LDL-C concentration appropriate to the individual. LDL-C treatment targets are based on pre-treatment risk and are as follows: <3 mmol/L in low- and moderate risk cases; <2.5 mmol/L and a reduction of at least 50% if the baseline concentration is 2.5 - 5.2 mmol/L in high-risk cases; and <1.8 mmol/L and a reduction of at least 50% if the baseline concentration is 1.8 - 3.5 mmol/L in very high-risk cases. A statin is usually recommended first-line; the specific agent is based on the required degree of cholesterol reduction, comorbidities and co-prescribed medication. Special attention should be paid to children with a family history of genetic or severe dyslipidaemia, who should be screened for dyslipidaemia from 8 years of age. In SA, HIV infection is not considered to be a significant cardiovascular risk factor and treatment recommendations for HIV-positive individuals are the same as for the general population, with careful choice of pharmacotherapy to avoid potential adverse drug-drug interactions. The benefit of statins in individuals older than 70 years is uncertain and clinical judgement should be used to guide treatment decisions and to avoid side-effects and overmedication in this group.

21 Guideline New joint consensus initiative on quantifying atherogenic lipoproteins. 2018

Stock, Jane K. ·European Atherosclerosis Society, Massans Gata 10, Box 5243, SE-402 24, Gothenburg, Sweden. Electronic address: office@eas-society.org. ·Atherosclerosis · Pubmed #30318139.

ABSTRACT: -- No abstract --

22 Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. 2018

Tobe, Sheldon W / Stone, James A / Anderson, Todd / Bacon, Simon / Cheng, Alice Y Y / Daskalopoulou, Stella S / Ezekowitz, Justin A / Gregoire, Jean C / Gubitz, Gord / Jain, Rahul / Keshavjee, Karim / Lindsay, Patty / L'Abbe, Mary / Lau, David C W / Leiter, Lawrence A / O'Meara, Eileen / Pearson, Glen J / Rabi, Doreen M / Sherifali, Diana / Selby, Peter / Tu, Jack V / Wharton, Sean / Walker, Kimberly M / Hua-Stewart, Diane / Liu, Peter P. ·Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta. · Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que. · St. Michael's Hospital (Cheng), University of Toronto, Toronto, Ont. · McGill University (Daskalopoulou), Montreal, Que. · Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta. · Institut de cardiologie de Montreal (Gregoire), Montreal, Que. · Universite de Montreal (Gubitz), Montreal, Que. · Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont. · Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont. · Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont. · Department of Nutritional Sciences (L'Abbe), University of Toronto, Toronto, Ont. · Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta. · Li Ka Shing Knowledge Institute (Leiter), St. Michael's Hospital, University of Toronto, Toronto, Ont. · Heart and Stroke Foundation (Lindsay), Ottawa, Ont. · Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont. · Insitut de Cardiologie de Montreal (O'Meara), Universite de Montreal, Montreal, Que. · Division of Cardiology, Mazankowski Alberta Heart Institute · University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta. · Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta. · Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont. · School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont. · Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta. · Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont. · ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont. · St. Joseph's Health Care Centre (Walker), Toronto, Ont. · McMaster University (Wharton), Hamilton Ont. · York University (Wharton), Toronto, Ont. ·CMAJ · Pubmed #30301743.

ABSTRACT: -- No abstract --

23 Guideline A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy). 2018

Descamps, Olivier S / Van Caenegem, Olivier / Hermans, Michel P / Balligand, Jean-Luc / Beauloye, Christophe / Bondue, Antoine / Carlier, Stéphane / Castermans, Emilie / Chenot, Fabien / Claeys, Marc / De Block, Christophe / de Leener, Anne / De Meester, Antoine / Demeure, Fabian / De Raedt, Herbert / Desmet, Walter / Elegeert, Ivan / Guillaume, Michel / Hoffer, Etienne / Kacenelenbogen, Raymond / Lancellotti, Patrizio / Langlois, Michel / Leone, Attilio / Mertens, Ann / Paquot, Nicolas / Vanakker, Olivier / Vanoverschelde, Jean-Louis / Verhaegen, Ann / Vermeersch, Pieter / Wallemacq, Caroline / Rietzschel, Ernst / Anonymous4790963. ·Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul and Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. Electronic address: olivier.descamps@jolimont.be. · Department of Cardiology, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. · Department of Endocrinology & Nutrition, UCL, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. · Department of Internal Medecine, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCL, Bruxelles, Belgium. · Department of Cardiology and Centre for Human Genetics, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. · Department of Cardiology, Centre Hospitalier Universitaire, Ambroise Paré and Mons University (UMONS), Mons, Belgium. · Department of Human Genetics, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium. · Department of Cardiology, Grand Hôpital de Charleroi, Belgium. · Department of Cardiology, University Hospital Antwerp, President of the Belgian Society of Cardiology, Belgium. · Department of Endocrinology-diabetology-metabolism, UA Antwerp University Hospital, UA Universitair Ziekenhuis Antwerpen, Belgium. · Centre de Génétique Humaine, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium. · Department of Cardiology, Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium. · Department of Cardiology, Cliniques Universitaires de Mont-Godinne, Belgium. · Department of Cardiology, Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium. · Department of Cardiovascular Medicine, Universitaire Ziekenhuizen Leuven, University Hospitals Leuven, Belgium. · Department of Cardiology, Algemeen Ziekenhuis, Groeninge, Kortrijk, Belgium. · Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Belgium. · Department of Cardiology, Centre Hospitalier Régional de la Citadelle, Liège, Belgium. · Department of Cardiology, CHU Saint-Pierre and President of the Working Group of Cardiovascular Readaptation and Prevention, Belgium. · GIGA Cardiovascular Sciences, Department of Cardiology, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium. · Department of laboratory Medicine, Algemeen Ziekenhuis Sint-Jan, Brugge, and National Representative of the Royal Belgian Society of Laboratory Medicine, Belgium. · Department of Cardiology, Centre Hospitalier Universitaire de Tivoli La Louvière, Belgium. · Department of Endocrinology, University Hospitals Leuven, Belgium. · GIGA I3, Department of Diabetes, Nutrition and Metabolic Diseases, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium. · Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium. · Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerpen, Belgium. · Department of laboratory Medicine, Senior Clinical Investigator of the Research Foundation-Flanders (FWO), University Hospital Leuven, The Royal Belgian Society of Laboratory Medicine, Belgium. · Department of Diabetes, Nutrition and Metabolic Diseases, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium. · Department of Cardiology, University Hospital Ghent and Ghent University, Belgium. ·Atherosclerosis · Pubmed #30270073.

ABSTRACT: BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein disorder characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly increased risk of premature cardiovascular disease (CVD). Because of the very high coronary artery disease risk associated with this condition, the prevalence of FH among patients admitted for CVD outmatches many times the prevalence in the general population. Awareness of this disease is crucial for recognizing FH in the aftermath of a hospitalization of a patient with CVD, and also represents a unique opportunity to identify relatives of the index patient, who are unaware they have FH. This article aims to describe a feasible strategy to facilitate the detection and management of FH among patients hospitalized for CVD. METHODS: A multidisciplinary national panel of lipidologists, cardiologists, endocrinologists and cardio-geneticists developed a three-step diagnostic algorithm, each step including three key aspects of diagnosis, treatment and family care. RESULTS: A sequence of tasks was generated, starting with the process of suspecting FH amongst affected patients admitted for CVD, treating them to LDL-C target, finally culminating in extensive cascade-screening for FH in their family. Conceptually, the pathway is broken down into 3 phases to provide the treating physicians with a time-efficient chain of priorities. CONCLUSIONS: We emphasize the need for optimal collaboration between the various actors, starting with a "vigilant doctor" who actively develops the capability or framework to recognize potential FH patients, continuing with an "FH specialist", and finally involving the patient himself as "FH ambassador" to approach his/her family and facilitate cascade screening and subsequent treatment of relatives.

24 Guideline Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. 2018

Ruiz-García, Antonio / Arranz-Martínez, Ezequiel / Morón-Merchante, Ignacio / Pascual-Fuster, Vicente / Tamarit, Juan J / Trias-Villagut, Ferran / Pintó-Sala, Xavier / Ascaso, Juan F / Anonymous4190956. ·Centro de Salud Universitario Pinto, Unidad de Lípidos y Prevención Cardiovascular, Universidad Europea de Madrid, Pinto, Madrid, España. · Centro de Salud San Blas, Parla, Madrid, España. · Centro de Salud Universitario Goya, Universidad Autónoma de Madrid, Madrid, España. · Centro de Salud Palleter, Universidad CEU-Cardenal Herrera, Castellón, España. Electronic address: pascual_vic@gva.es. · Consorcio Hospital General Universitario, Valencia, España. · Hospital de Bellvitge, Universitat de Barcelona, Barcelona, España. · Hospital Clínico-Universitat de València, INCLIVA Research Institute, CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), ISCIII, Valencia, España. ·Clin Investig Arterioscler · Pubmed #30053980.

ABSTRACT: A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Laboratorios Esteve, S.A.

25 Guideline Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". 2018

Moulin, Philippe / Dufour, Robert / Averna, Maurizio / Arca, Marcello / Cefalù, Angelo B / Noto, Davide / D'Erasmo, Laura / Di Costanzo, Alessia / Marçais, Christophe / Alvarez-Sala Walther, Luis Antonio / Banach, Maciej / Borén, Jan / Cramb, Robert / Gouni-Berthold, Ioanna / Hughes, Elizabeth / Johnson, Colin / Pintó, Xavier / Reiner, Željko / van Lennep, Jeanine Roeters / Soran, Handrean / Stefanutti, Claudia / Stroes, Erik / Bruckert, Eric. ·Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon, INSERM UMR 1060 Carmen, Université Claude Bernard Lyon 1, Lyon, France. · Institut de Recherches Cliniques de Montréal, Montréal, Canada. · Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), University of Palermo, Palermo, Italy. · Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy. · Hospital General Universitario Gregorio Marañón, IiSGM, Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. · Medical University of Lodz, Lodz, Poland. · University of Gothenburg, Gothenburg, Sweden. · University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. · Polyclinic for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne, Cologne, Germany. · Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK. · University Hospital, Southampton, UK. · Bellvitge University Hospital, Barcelona, Spain. · University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. · Erasmus Medical Centre, Rotterdam, the Netherlands. · Central Manchester University Hospital NHS Foundation Trust, Manchester, UK. · Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. · Academic Medical Center, Amsterdam, the Netherlands. · Hôpital Pitié Salpêtrière, Paris, France. Electronic address: eric.bruckert@aphp.fr. ·Atherosclerosis · Pubmed #29980054.

ABSTRACT: Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of European experts provided guidance on the diagnostic strategy surrounding FCS and proposed an algorithm-based diagnosis tool for identification of these patients, which can be readily translated into practice. Features included in this FCS score comprise: severe elevation of plasma TGs (fasting TG levels >10 mmol/L [885 mg/dL] on multiple occasions), refractory to standard TG-lowering therapies, a young age at onset, the lack of secondary factors (except for pregnancy and oral oestrogens) and a history of episodes of acute pancreatitis. Considering 53 FCS patients from three cohorts and 52 MCS patients from three cohorts, the overall sensitivity of the FCS score (≥10) was 88% (95% confidence interval [CI]: 0.76, 0.97) with an overall specificity of 85% (95% CI: 0.75, 0.94). Receiver operating characteristic curve area was 0.91. Pragmatic clinical scoring, by standardising diagnosis, may help differentiate FCS from MCS, may alleviate the need for systematic genotyping in patients with severe HTG and may help identify high-priority candidates for genotyping.

Next